- Home
- WST vs DXCM Comparison
WST vs DXCM Comparison
Compare WST & DXCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WST
- DXCM
- Stock Information
- Founded
- WST 1923
- DXCM 1999
- Country
- WST United States
- DXCM United States
- Employees
- WST N/A
- DXCM N/A
- Industry
- WST Medical/Dental Instruments
- DXCM Medical/Dental Instruments
- Sector
- WST Health Care
- DXCM Health Care
- Exchange
- WST Nasdaq
- DXCM Nasdaq
- Market Cap
- WST 15.6B
- DXCM 34.1B
- IPO Year
- WST N/A
- DXCM 2005
- Fundamental
- Price
- WST $227.12
- DXCM $83.52
- Analyst Decision
- WST Buy
- DXCM Strong Buy
- Analyst Count
- WST 7
- DXCM 20
- Target Price
- WST $331.67
- DXCM $98.50
- AVG Volume (30 Days)
- WST 646.1K
- DXCM 3.8M
- Earning Date
- WST 07-24-2025
- DXCM 07-30-2025
- Dividend Yield
- WST 0.37%
- DXCM N/A
- EPS Growth
- WST N/A
- DXCM N/A
- EPS
- WST 6.37
- DXCM 1.33
- Revenue
- WST $2,895,800,000.00
- DXCM $4,148,000,000.00
- Revenue This Year
- WST $3.38
- DXCM $16.74
- Revenue Next Year
- WST $5.85
- DXCM $15.29
- P/E Ratio
- WST $35.63
- DXCM $62.58
- Revenue Growth
- WST N/A
- DXCM 9.11
- 52 Week Low
- WST $187.43
- DXCM $57.52
- 52 Week High
- WST $352.33
- DXCM $117.19
- Technical
- Relative Strength Index (RSI)
- WST 59.84
- DXCM 49.26
- Support Level
- WST $219.60
- DXCM $82.73
- Resistance Level
- WST $233.84
- DXCM $85.92
- Average True Range (ATR)
- WST 5.29
- DXCM 2.63
- MACD
- WST 0.60
- DXCM -0.09
- Stochastic Oscillator
- WST 66.82
- DXCM 54.33
About WST West Pharmaceutical Services Inc.
West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs, which include large molecule biologics, peptides such as GLP-1 receptor agonists, and small molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
About DXCM DexCom Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.